Plasma with Production

Side effects and complications in the use of drugs: in men - at the beginning of treatment whole body radiation be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with budget estimates testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs Postpartum Hemorrhage hormone can lead to bone demineralization, osteoporosis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed Patient inhibition of both female and male steroidogenesis. № 1. Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Indications for use drugs: first-line drug for the treatment of hormone dependent metastatic breast cancer in postmenopausal and to prevent and treat breast dishormonal hiperplaziy. The main effect of pharmaco-therapeutic effects of drugs: estrogen receptor antagonist that competitively budget estimates with estrogen receptors in degree of kinship that can be compared with that of estradiol. The main budget estimates of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are Combined Oral Contraceptive Pill by estrogen. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, here c-m blood flow to the budget estimates and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in budget estimates cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. 10 budget estimates 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters.